One representative example illustrating the potential of surface‐engineered EVs involves the use of tumor‐specific peptide neoantigens conjugated to CP05, a synthetic anchor peptide with high affinity for CD63[127] Through co‐incubation, CP05‐fused neoantigens were selectively and stably anchored onto the EV membrane. Here, CD63 is linked to neoplasm.